Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing-Reference-Cited by-同舟云学术

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Published:2021-02 Issue:2 Volume:23 Page:181-199
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Ho Caleb^ORCID,Syed Mustafa,Roshal Mikhail,Petrova-Drus Kseniya,Moung Christine^ORCID,Yao Jinjuan,Quesada Andres E.,Benhamida Jamal,Vanderbilt Chad^ORCID,Liu Ying,Zhu Menglei^ORCID,Yu Wayne,Maciag Lidia,Wang Meiyi,Ma Yuanyuan,Gao Qi,Rustad Even H.,Hultcrantz Malin,Diamond Benjamin T.,Zheng-Lin Binbin^ORCID,Huang Ying^ORCID,Hutt Kasey^ORCID,Miller Jeffrey E.,Dogan Ahmet,Nafa Khedoudja^ORCID,Landgren Ola^ORCID,Arcila Maria E.

Funder

Memorial Sloan-Kettering Cancer Center

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference28 articles.

1. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant;Bladé;Br J Haematol,1998

2. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

3. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016

4. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma;Paiva;Blood,2012

5. New criteria for response assessment: role of minimal residual disease in multiple myeloma;Paiva;Blood,2016

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Single-Tube Next Generation Sequencing Assay for B-Cell Receptor Clonality Testing;Journal of Molecular Pathology;2024-02-02

2. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms;The Journal of Molecular Diagnostics;2023-12

3. MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma;Blood Cancer Discovery;2023-09-01

4. Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing;Oncotarget;2023-05-12

5. Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing;Experimental Hematology;2023-03